Cancer

Company Deals

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

IMPACT Therapeutics, Inc. (HKG: 7630) announced an exclusive partnership with Pharmanovia for senaparib (brand name:...

Company Deals

BeOne Medicines and Revolution Medicines Announce Clinical Collaboration and Regional Licensing Deal on RAS(ON) Inhibitors Across Select Asian Markets

Fineline Cube Aug 11, 2026

BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced a multifaceted collaboration agreement with...

Company Drug

BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities

Fineline Cube Aug 11, 2026

BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that Imdelltra (tarlatamab for injection)...

Company Deals

Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL

Fineline Cube Aug 11, 2026

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced a collaboration with TwinEdge Bioscience, a cutting‑edge...

Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Fineline Cube Aug 7, 2026

CARsgen Therapeutics (HKG: 2171) announced that its allogeneic CAR-T cell therapy CT1190B has received clinical...

Company Drug

TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations

Fineline Cube Aug 7, 2026

TransThera Sciences (HKG: 2617) announced that China’s National Medical Products Administration (NMPA) has granted conditional...

Company Drug

Eli Lilly’s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer

Fineline Cube Aug 6, 2026

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

Novartis’ Pluvicto Receives FDA Approval for Metastatic Hormone-Sensitive Prostate Cancer

Fineline Cube Aug 4, 2026

Novartis (NYSE: NVS) announced that the U.S. Food and Drug Administration (FDA) has approved Pluvicto...

Company Drug

CSPC Pharmaceutical Launches Phase Ib/II Trial of Novel SYS6090 Fusion Protein for Colorectal Cancer

Fineline Cube Aug 4, 2026

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that a Phase Ib/II clinical trial of SYS6090...

Company Drug

CSPC Pharmaceutical Launches Phase II Trial of Novel ADC SYS6041 for Recurrent Ovarian Cancer in China

Fineline Cube Aug 4, 2026

CSPC Pharmaceutical Group (HKG: 1093) announced that a Phase II clinical trial evaluating its self-developed...

Company Drug

Nanjing Leads Biolabs Secures NMPA Approval for Opamtistomig (LBL-024) in Metastatic Colorectal Cancer Clinical Trial

Fineline Cube Aug 4, 2026

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

CSPC Pharmaceutical’s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma

Fineline Cube Jul 30, 2026

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that CRB-701 (SYS 6002), a next-generation antibody-drug conjugate...

Company Drug

Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval

Fineline Cube Jul 30, 2026

Akeso, Inc. (HKG: 9926) and Shanghai Allink Biotherapeutics Inc. announced a clinical research collaboration to...

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership

Fineline Cube Jul 29, 2026

Hansoh Pharmaceutical (HKG: 3692) announced that its pivotal Phase III ARTEMIS-011 clinical trial of Risvutatug...

Company Drug

Insilico Medicine’s AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma

Fineline Cube Jul 29, 2026

Insilico Medicine (HKG: 3696) announced that ISM6331, a novel pan-TEAD inhibitor discovered through the company’s...

Company Drug

CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor

Fineline Cube Jul 28, 2026

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its self-developed Class...

Company Drug

Bio-Sincerity’s First-in-Class Epigenetic Inhibitor BIOS0635-048 Receives NMPA Clearance for Advanced Solid Tumor Trials

Fineline Cube Jul 28, 2026

Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) announced that BIOS0635-048 tablets have received approval from...

Company Drug

Sichuan Biokin’s HER2 ADC T-Bren Enters Phase III Trial for Biliary Tract Cancer After Platinum Failure

Fineline Cube Jul 27, 2026

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its self-developed innovative biologic drug, T-Bren...

Company Drug

Gilead’s Trodelvy Receives Positive CHMP Opinion for First-Line TNBC Treatment in Combination with Keytruda

Fineline Cube Jul 27, 2026

Gilead Sciences Inc. (NASDAQ: GILD) announced that the Committee for Medicinal Products for Human Use...

Company Drug

GSK Secures Early FDA Approval for Jideytro – ROS1 Inhibitor for Resistant Non-Small Cell Lung Cancer

Fineline Cube Jul 23, 2026

GlaxoSmithKline plc (GSK) (NYSE: GSK) announced on July 22, 2026 that the U.S. Food and...

Cancer

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

BeOne Medicines and Revolution Medicines Announce Clinical Collaboration and Regional Licensing Deal on RAS(ON) Inhibitors Across Select Asian Markets

BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities

Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations

Eli Lilly’s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer

Novartis’ Pluvicto Receives FDA Approval for Metastatic Hormone-Sensitive Prostate Cancer

CSPC Pharmaceutical Launches Phase Ib/II Trial of Novel SYS6090 Fusion Protein for Colorectal Cancer

CSPC Pharmaceutical Launches Phase II Trial of Novel ADC SYS6041 for Recurrent Ovarian Cancer in China

Nanjing Leads Biolabs Secures NMPA Approval for Opamtistomig (LBL-024) in Metastatic Colorectal Cancer Clinical Trial

CSPC Pharmaceutical’s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma

Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval

Hansoh Pharmaceutical’s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership

Insilico Medicine’s AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma

CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor

Bio-Sincerity’s First-in-Class Epigenetic Inhibitor BIOS0635-048 Receives NMPA Clearance for Advanced Solid Tumor Trials

Sichuan Biokin’s HER2 ADC T-Bren Enters Phase III Trial for Biliary Tract Cancer After Platinum Failure

Gilead’s Trodelvy Receives Positive CHMP Opinion for First-Line TNBC Treatment in Combination with Keytruda

GSK Secures Early FDA Approval for Jideytro – ROS1 Inhibitor for Resistant Non-Small Cell Lung Cancer

You Missed

Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal

NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026